Vascular risk factor control and adherence to secondary preventive medication after ischaemic stroke

Studies regarding adequacy of secondary stroke prevention are limited. We report medication adherence, risk factor control and factors influencing vascular risk profile following ischaemic stroke.

[1]  H. Sillo,et al.  Utilization Trends of Antiviral and Antifungal Agents for Human Systemic Use in Tanzania From 2010 to 2017 Using the World Health Organization Collaborating Centre for Drug Statistics Methodology , 2021, Frontiers in Tropical Diseases.

[2]  Dominique Hansen,et al.  Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. , 2020, European journal of preventive cardiology.

[3]  S. Pendlebury,et al.  Impact of different methods defining post‐stroke neurocognitive disorder: The Nor‐COAST study , 2020, Alzheimer's & dementia.

[4]  D. Melzer,et al.  Blood pressure in frail older adults: associations with cardiovascular outcomes and all-cause mortality , 2020, Age and ageing.

[5]  P. Toth,et al.  Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis , 2019, Lipids in Health and Disease.

[6]  I. Hetlevik,et al.  Stroke follow-up in primary care: a prospective cohort study on guideline adherence , 2018, BMC Family Practice.

[7]  S. Pendlebury,et al.  The Norwegian Cognitive impairment after stroke study (Nor-COAST): study protocol of a multicentre, prospective cohort study , 2018, BMC Neurology.

[8]  B. Norrving,et al.  Action Plan for Stroke in Europe 2018–2030 , 2018, European stroke journal.

[9]  Webb Ajs.,et al.  Action Plan for Stroke in Europe , 2018 .

[10]  P. Amarenco,et al.  Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. , 2018, The New England journal of medicine.

[11]  E. Vicaut,et al.  Five‐Year Risk of Stroke after TIA or Minor Ischemic Stroke , 2018, The New England journal of medicine.

[12]  P. Rothwell,et al.  Long‐Term Risk of Myocardial Infarction Compared to Recurrent Stroke After Transient Ischemic Attack and Ischemic Stroke: Systematic Review and Meta‐Analysis , 2018, Journal of the American Heart Association.

[13]  U. Laufs,et al.  Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins , 2017, Clinical Research in Cardiology.

[14]  J. De Sutter,et al.  Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999-2013. , 2017, Global heart.

[15]  D. Atar,et al.  Gender differences in the effects of cardiovascular drugs , 2017, European heart journal. Cardiovascular pharmacotherapy.

[16]  T. Dammen,et al.  Unfavourable risk factor control after coronary events in routine clinical practice , 2017, BMC Cardiovascular Disorders.

[17]  Ivy Shiue,et al.  Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2016, The Lancet Neurology.

[18]  M. Walters,et al.  Predictive factors of non-adherence to secondary preventative medication after stroke or transient ischaemic attack: A systematic review and meta-analyses , 2016, European stroke journal.

[19]  Stefan Störk,et al.  EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries , 2016, European journal of preventive cardiology.

[20]  E. Dolan,et al.  Secondary prevention after ischaemic stroke: the ASPIRE-S study , 2015, BMC Neurology.

[21]  P. Heuschmann,et al.  Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey , 2015, European journal of preventive cardiology.

[22]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2014, Diabetes Care.

[23]  E. Rietzschel,et al.  Factors associated with clinical inertia: an integrative review , 2014, Advances in medical education and practice.

[24]  Bohdana Ratitch,et al.  Clinical Trials with Missing Data: A Guide for Practitioners , 2014 .

[25]  G. Hankey.  Secondary stroke prevention , 2014, The Lancet Neurology.

[26]  O. Spigset,et al.  Adherence to medication for chronic disorders during pregnancy: results from a multinational study , 2014, International Journal of Clinical Pharmacy.

[27]  Hassan Khan,et al.  Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. , 2013, European heart journal.

[28]  N. Skolnik,et al.  Management of Hyperglycemia in Type 2 Diabetes , 2012 .

[29]  E. Peterson,et al.  Secondary preventive medication persistence and adherence 1 year after stroke , 2011, Neurology.

[30]  P. Heuschmann,et al.  Risk and Cumulative Risk of Stroke Recurrence: A Systematic Review and Meta-Analysis , 2011, Stroke.

[31]  W. Oczkowski,et al.  Stroke prevention care delivery: predictors of risk factor management outcomes. , 2011, International journal of nursing studies.

[32]  M. Woodward,et al.  Predictors of Nonadherence to Statins: A Systematic Review and Meta-Analysis , 2010, The Annals of pharmacotherapy.

[33]  E. Glader,et al.  Persistent Use of Secondary Preventive Drugs Declines Rapidly During the First 2 Years After Stroke , 2010, Stroke.

[34]  Lawrence A Leiter,et al.  Applying the Evidence: Do Patients With Stroke, Coronary Artery Disease, or Both Achieve Similar Treatment Goals? , 2009, Stroke.

[35]  J. Spence,et al.  Combining Multiple Approaches for the Secondary Prevention of Vascular Events After Stroke: A Quantitative Modeling Study , 2007, Stroke.

[36]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[37]  A. L. Dal-Fabbro,et al.  Adherence to long term therapies: evidence for action , 2005 .

[38]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[39]  R. Snaith,et al.  The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.

[40]  L. Fried,et al.  Frailty in older adults: evidence for a phenotype. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[41]  Per Capita,et al.  About the authors , 1995, Machine Vision and Applications.

[42]  L. Green,et al.  Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence , 1986, Medical care.

[43]  B. Reisberg,et al.  The Global Deterioration Scale for assessment of primary degenerative dementia. , 1982, The American journal of psychiatry.

[44]  K. Khunti,et al.  Interventions for improving modifiable risk factor control in the secondary prevention of stroke. , 2018, The Cochrane database of systematic reviews.

[45]  V. Chair,et al.  Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. , 2014, Stroke.

[46]  B. Guthrie,et al.  Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity. , 2013, Age and ageing.

[47]  J. Ceral,et al.  Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy , 2011, Hypertension Research.

[48]  William Branch,et al.  Clinical Inertia , 2001, Annals of Internal Medicine.

[49]  A. U. Rickel,et al.  Guidelines for Prevention, I , 1998 .